Inhaled corticosteroids in chronic obstructive pulmonary disease: A pro-con perspective

British Journal of Clinical Pharmacology

Volumn 78, Issue 2, 2014, Pages 282-300

  Babu, K Suresh ^a   Kastelik, Jack A ^b,c   Morjaria, Jaymin B ^b,c  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^b CASTLE HILL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF HULL   (United Kingdom)

Author keywords

adverse events; budesonide formoterol; fluticasone salmeterol; inhaled corticosteroids; mortality; pneumonia

Indexed keywords

CORTICOSTEROID; ANTIINFLAMMATORY AGENT;

CANDIDIASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DIABETES MELLITUS; DISEASE EXACERBATION; HEALTH STATUS; HOARSENESS; HUMAN; HYPERGLYCEMIA; LUNG FUNCTION; META ANALYSIS (TOPIC); MORTALITY; OSTEOPOROSIS; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY TRACT INFLAMMATION; REVIEW; SORE THROAT; SPINE FRACTURE; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMATIC REVIEW (TOPIC); UPPER RESPIRATORY TRACT INFECTION; IMMUNOLOGY; LUNG FUNCTION TEST; PRACTICE GUIDELINE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; HUMANS; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX;

EID: 84904858401     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12334     Document Type: Review

References (166)

1. Global Inititaive for Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2011.
2. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE,. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233-239.
3. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93: 391-398.
4. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J,. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
5. Pauwels RA, Löfdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV,. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948-1953.
6. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK,. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.
7. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM,. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1304-1309.
8. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD,. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
9. Pizzichini E, Pizzichini MM, Gibson P, Parameswaran K, Gleich GJ, Berman L, Dolovich J, Hargreave FE,. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998; 158 (5 Pt 1): 1511-1517.
10. O'Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK,. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997; 155: 852-857.
11. Saetta M, Di Stefano A, Turato G, Facchini FM, Corbino L, Mapp CE, Maestrelli P, Ciaccia A, Fabbri LM,. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157 (3 Pt 1): 822-826.
12. Stanescu D, Sanna A, Veriter C, Kostianev S, Calcagni PG, Fabbri LM, Maestrelli P,. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996; 51: 267-271.
13. Rutgers SR, Timens W, Kaufmann HF, van der Mark TW, Koeter GH, Postma DS,. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J 2000; 15: 109-115.
14. Gan WQ, Man SF, Senthilselvan A, Sin DD,. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574-580.
15. Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, Vestbo J, Lomas DA, Calverley PM, Wouters E, Crim C, Yates JC, Silverman EK, Coxson HO, Bakke P, Mayer RJ, Celli B,. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012; 7: e37483.
16. John M, Bosse S, Oltmanns U, Schumacher A, Witt C,. Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease. Respir Med 2005; 99: 1418-1424.
17. Sin DD, Man SF, Marciniuk DD, Ford G, FitzGerald M, Wong E, York E, Mainra RR, Ramesh W, Melenka LS, Wilde E, Cowie RL, Williams D, Gan WQ, Rousseau R,. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 1207-1214.
18. Saetta M, Turato G, Facchini FM, Corbino L, Lucchini RE, Casoni G, Maestrelli P, Mapp CE, Ciaccia A, Fabbri LM,. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. Am J Respir Crit Care Med 1997; 156: 1633-1639.
19. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC,. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002; 165: 1592-1596.
20. Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, Johnson M, Thomson NC, Jeffery PK,. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006; 173: 736-743.
21. Lapperre TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, van Schadewijk A, Thiadens HA, Vonk JM, Boezen HM, Ten Hacken NH, Sont JK, Rabe KF, Kerstjens HA, Hiemstra PS, Timens W, Postma DS, Sterk PJ,. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2009; 151: 517-527.
22. Thompson AB, Mueller MB, Heires AJ, Bohling TL, Daughton D, Yancey SW, Sykes RS, Rennard SI,. Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation. Am Rev Respir Dis 1992; 146: 389-395.
23. Ozol D, Aysan T, Solak ZA, Mogulkoc N, Veral A, Sebik F,. The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients. Respir Med 2005; 99: 1494-1500.
24. Bathoorn E, Liesker JJ, Postma DS, Boorsma M, Bondesson E, Koeter GH, Kauffman HF, van Oosterhout AJ, Kerstjens HA,. Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations. COPD 2008; 5: 282-290.
25. Gan WQ, Man SF, Sin DD,. Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm Med 2005; 5: 3.
26. Jen R, Rennard SI, Sin DD,. Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 2012; 7: 587-595.
27. Sin DD, Lacy P, York E, Man SF,. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 760-765.
28. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, Barnes PJ,. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352: 1967-1976.
29. Barnes PJ, Ito K, Adcock IM,. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004; 363: 731-733.
30. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ,. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155: 542-548.
31. Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, Barnes PJ,. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160 (5 Pt 1): 1635-1639.
32. Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R, Berry M, Parker D, Monteiro W, Pavord ID, Bradding P,. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005; 60: 193-198.
33. Boorsma M, Lutter R, van de Pol MA, Out TA, Jansen HM, Jonkers RE,. Long-term effects of budesonide on inflammatory status in COPD. COPD 2008; 5: 97-104.
34. Verhoeven GT, Wijkhuijs AJ, Hooijkaas H, Hoogsteden HC, Sluiter W,. Effect of an inhaled glucocorticoid on reactive oxygen species production by bronchoalveolar lavage cells from smoking COPD patients. Mediators Inflamm 2000; 9: 109-113.
35. Verhoeven GT, Hegmans JP, Mulder PG, Bogaard JM, Hoogsteden HC, Prins JB,. Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax 2002; 57: 694-700.
36. Bourbeau J, Christodoulopoulos P, Maltais F, Yamauchi Y, Olivenstein R, Hamid Q,. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007; 62: 938-943.
37. Seemungal TA, Hurst JR, Wedzicha JA,. Exacerbation rate, health status and mortality in COPD-a review of potential interventions. Int J Chron Obstruct Pulmon Dis 2009; 4: 203-223.
38. Siva R, Green RH, Brightling CE, Shelley M, Hargadon B, McKenna S, Monteiro W, Berry M, Parker D, Wardlaw AJ, Pavord ID,. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007; 29: 906-913.
39. Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, Lomas DA, Barer MR, Johnston SL, Pavord ID, Brightling CE,. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012; 186: 48-55.
40. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC,. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16: 5-40.
41. Gladysheva ES, Malhotra A, Owens RL,. Influencing the decline of lung function in COPD: use of pharmacotherapy. Int J Chron Obstruct Pulmon Dis 2010; 5: 153-164.
42. Fletcher C, Peto R,. The natural history of chronic airflow obstruction. Br Med J 1977; 1: 1645-1648.
43. Ryan G, Knuiman MW, Divitini ML, James A, Musk AW, Bartholomew HC,. Decline in lung function and mortality: the Busselton Health Study. J Epidemiol Community Health 1999; 53: 230-234.
44. Mannino DM, Reichert MM, Davis KJ,. Lung function decline and outcomes in an adult population. Am J Respir Crit Care Med 2006; 173: 985-990.
45. Pauwels RA, Lofdahl CG, Pride NB, Postma DS, Laitinen LA, Ohlsson SV,. European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. Eur Respir J 1992; 5: 1254-1261.
46. Calverley PM, Kuna P, Monso E, Costantini M, Petruzzelli S, Sergio F, Varoli G, Papi A, Brusasco V,. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respir Med 2010; 104: 1858-1868.
47. van Grunsven PM, van Schayck CP, Derenne JP, Kerstjens HA, Renkema TE, Postma DS, Similowski T, Akkermans RP, Pasker-de Jong PC, Dekhuijzen PN, van Herwaarden CL, van Weel C,. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax 1999; 54: 7-14.
48. Sutherland ER, Allmers H, Ayas NT, Venn AJ, Martin RJ,. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003; 58: 937-941.
49. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM,. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-338.
50. Vestbo J, Sørensen T, Lange P, Brix A, Torre P, Viskum K,. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-1823.
51. Lung Health Study Resarch Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-1909.
52. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H,. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81.
53. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H,. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-919.
54. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C,; TRial of Inhaled STeroids ANd long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456.
55. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T,. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 1084-1091.
56. Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, Lettis S, Crim C, Calverley PM,. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013; 1: 210-223.
57. Yang IA, Clarke MS, Sim EH, Fong KM,. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; (7) CD002991.
58. Spencer S, Karner C, Cates CJ, Evans DJ,. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011; (12) CD007033.
59. Rodrigo GJ, Castro-Rodriguez JA, Plaza V,. Safety and efficacy of combined long-acting β-agonists and inhaled corticosteroids vs long-acting β-agonists monotherapy for stable COPD: a systematic review. Chest 2009; 136: 1029-1038.
60. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M,. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146: 545-555.
61. Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC,. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005; 60: 480-487.
62. Suissa S, Ernst P, Vandemheen KL, Aaron SD,. Methodological issues in therapeutic trials of COPD. Eur Respir J 2008; 31: 927-933.
63. Suissa S, Ernst P,. Mega trials in COPD-clinical data analysis and design issues. Pneumonol Alergol Pol 2011; 79: 227-231.
64. Suissa S,. Medications to modify lung function decline in chronic obstructive pulmonary disease: some hopeful signs. Am J Respir Crit Care Med 2008; 178: 322-323.
65. van Manen JG, Bindels PJ, Dekker FW, Bottema BJ, van der Zee JS, Ijzermans CJ, Schade E,. The influence of COPD on health-related quality of life independent of the influence of comorbidity. J Clin Epidemiol 2003; 56: 1177-1184.
66. Ståhl E, Lindberg A, Jansson SA, Rönmark E, Svensson K, Andersson F, Löfdahl CG, Lundbäck B,. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 2005; 3: 56.
67. Mahler DA, Tomlinson D, Olmstead EM, Tosteson AN, O'Connor GT,. Changes in dyspnea, health status, and lung function in chronic airway disease. Am J Respir Crit Care Med 1995; 151: 61-65.
68. Weatherall M, Marsh S, Shirtcliffe P, Williams M, Travers J, Beasley R,. Quality of life measured by the St George's Respiratory Questionnaire and spirometry. Eur Respir J 2009; 33: 1025-1030.
69. Jones PW,. Health status and the spiral of decline. COPD 2009; 6: 59-63.
70. Voll-Aanerud M, Eagan TM, Plana E, Omenaas ER, Bakke PS, Svanes C, Siroux V, Pin I, Antõ JM, Leynaert B,. Respiratory symptoms in adults are related to impaired quality of life, regardless of asthma and COPD: results from the European community respiratory health survey. Health Qual Life Outcomes 2010; 8: 107.
71. Ware JE Jr, Sherbourne CD,. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-483.
72. Jones PW, Quirk FH, Baveystock CM,. The St George's respiratory questionnaire. Respir Med 1991; 85 (Suppl B): 25-31; discussion 3-7.
73. Williams JE, Singh SJ, Sewell L, Guyatt GH, Morgan MD,. Development of a self-reported Chronic Respiratory Questionnaire (CRQ-SR). Thorax 2001; 56: 954-959.
74. Ai-Kassimi FA, Alhamad EH,. Chronic obstructive pulmonary disease lost in translation: why are the inhaled corticosteroids skeptics refusing to go? Ann Thorac Med 2013; 8: 8-13.
75. Jones PW,. Quality of life, symptoms and pulmonary function in asthma: long-term treatment with nedocromil sodium examined in a controlled multicentre trial. Nedocromil Sodium Quality of Life Study Group. Eur Respir J 1994; 7: 55-62.
76. Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ,. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med 2012; 106: 257-268.
77. Choudhury AB, Dawson CM, Kilvington HE, Eldridge S, James WY, Wedzicha JA, Feder GS, Griffiths CJ,. Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respir Res 2007; 8: 93.
78. Spencer S, Calverley PM, Sherwood Burge P, Jones PW,. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 122-128.
79. Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C,. Effect of fluticasone propionate/salmeterol (250/50 μg) or salmeterol (50 μg) on COPD exacerbations. Respir Med 2008; 102: 1099-1108.
80. Anzueto A, Ferguson GT, Feldman G, Chinsky K, Seibert A, Emmett A, Knobil K, O'Dell D, Kalberg C, Crater G,. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 2009; 6: 320-329.
81. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA,. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157 (5 Pt 1): 1418-1422.
82. Kessler R, Ståhl E, Vogelmeier C, Haughney J, Trudeau E, Löfdahl CG, Partridge MR,. Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest 2006; 130: 133-142.
83. Spencer S, Calverley PM, Burge PS, Jones PW,. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004; 23: 698-702.
84. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA,. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
85. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R,. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925-931.
86. Gunen H, Hacievliyagil SS, Kosar F, Mutlu LC, Gulbas G, Pehlivan E, Sahin I, Kizkin O,. Factors affecting survival of hospitalised patients with COPD. Eur Respir J 2005; 26: 234-241.
87. Seneff MG, Wagner DP, Wagner RP, Zimmerman JE, Knaus WA,. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995; 274: 1852-1857.
88. Kardos P, Wencker M, Glaab T, Vogelmeier C,. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 144-149.
89. Alsaeedi A, Sin DD, McAlister FA,. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002; 113: 59-65.
90. Nannini L, Cates CJ, Lasserson TJ, Poole P,. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007; (4) CD003794.
91. Bourbeau J, Rouleau MY, Boucher S,. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax 1998; 53: 477-482.
92. Renkema TE, Schouten JP, Koeter GH, Postma DS,. Effects of long-term treatment with corticosteroids in COPD. Chest 1996; 109: 1156-1162.
93. Senderovitz T, Vestbo J, Frandsen J, Maltbaek N, Nørgaard M, Nielsen C, Kampmann JP,. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society of Respiratory Medicine. Respir Med 1999; 93: 715-718.
94. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J,. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998; 351: 773-780.
95. Suissa S,. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 842-846.
96. Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T,. The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124: 834-843.
97. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA,; INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177: 19-26.
98. Schermer T, Chavannes N, Dekhuijzen R, Wouters E, Muris J, Akkermans R, van Schayck O, van Weel C,. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir Med 2009; 103: 542-551.
99. Shaker SB, Dirksen A, Ulrik CS, Hestad M, Stavngaard T, Laursen LC, Maltbaek N, Clementsen P, Skjaerbaek N, Nielsen L, Stoel B, Skovgaard LT, Tonnesen P,. The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. COPD 2009; 6: 104-111.
100. Agarwal R, Aggarwal AN, Gupta D, Jindal SK,. Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials. Chest 2010; 137: 318-325.
101. Aaron SD, Fergusson D, Marks GB, Suissa S, Vandemheen KL, Doucette S, Maltais F, Bourbeau JF, Goldstein RS, Balter M, O'Donnell D, Fitzgerald M,. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax 2008; 63: 122-128.
102. Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP,. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 948-955.
103. Bale G, Martinez-Camblor P, Burge PS, Soriano JB,. Long-term mortality follow-up of the ISOLDE participants: causes of death during 13 years after trial completion. Respir Med 2008; 102: 1468-1472.
104. Lindberg A, Larsson LG, Muellerova H, Rönmark E, Lundbäck B,. Up-to-date on mortality in COPD-report from the OLIN COPD study. BMC Pulm Med 2012; 12: 1.
105. Kim V, Benditt JO, Wise RA, Sharafkhaneh A,. Oxygen therapy in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5: 513-518.
106. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC,. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002; 20: 819-825.
107. Soriano JB, Kiri VA, Pride NB, Vestbo J,. Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2003; 2: 67-74.
108. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J,. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009; 10: 59.
109. Sin DD, Wu L, Anderson JA, Anthonisen NR, Buist AS, Burge PS, Calverley PM, Connett JE, Lindmark B, Pauwels RA, Postma DS, Soriano JB, Szafranski W, Vestbo J,. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60: 992-997.
110. Fan VS, Bryson CL, Curtis JR, Fihn SD, Bridevaux PO, McDonell MB, Au DH,. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysis. Am J Respir Crit Care Med 2003; 168: 1488-1494.
111. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E,. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300: 2407-2416.
112. Sin DD, Tu JV,. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 580-584.
113. Suissa S,. Inhaled steroids and mortality in COPD: bias from unaccounted immortal time. Eur Respir J 2004; 23: 391-395.
114. Suissa S,. Observational studies of inhaled corticosteroids in chronic obstructive pulmonary disease: misconstrued immortal time bias. Am J Respir Crit Care Med 2006; 173: 464; author reply 464-5.
115. Suissa S,. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008; 167: 492-499.
116. Kiri VA, Bettoncelli G, Testi R, Viegi G,. Inhaled corticosteroids are more effective in COPD patients when used with LABA than with SABA. Respir Med 2005; 99: 1115-1124.
117. La Vecchia C, Fabbri LM,. Prevention of death in COPD. N Engl J Med 2007; 356: 2211-2212, author reply 3-4.
118. Huiart L, Ernst P, Ranouil X, Suissa S,. Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J 2005; 25: 634-639.
119. Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB,. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008; 149: 380-390.
120. Macie C, Wooldrage K, Manfreda J, Anthonisen NR,. Inhaled corticosteroids and mortality in COPD. Chest 2006; 130: 640-646.
121. Loke YK, Kwok CS, Singh S,. Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD. Eur Respir J 2010; 35: 1003-1021.
122. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, MacNee W, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Wouters E, Yates JC, Vestbo J,. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11: 122.
123. Iversen KK, Kjaergaard J, Akkan D, Kober L, Torp-Pedersen C, Hassager C, Vestbo J, Kjoller E,; ECHOS-Lung Function Study Group. Chronic obstructive pulmonary disease in patients admitted with heart failure. J Intern Med 2008; 264: 361-369.
124. Hawkins NM, Jhund PS, Simpson CR, Petrie MC, Macdonald MR, Dunn FG, Macintyre K, McMurray JJ,. Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. Eur J Heart Fail 2010; 12: 17-24.
125. Fabbri LM, Luppi F, Beghe B, Rabe KF,. Complex chronic comorbidities of COPD. Eur Respir J 2008; 31: 204-212.
126. Hanania NA, Mullerova H, Locantore NW, Vestbo J, Watkins ML, Wouters EF, Rennard SI, Sharafkhaneh A,. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med 2011; 183: 604-611.
127. Kunik ME, Roundy K, Veazey C, Souchek J, Richardson P, Wray NP, Stanley MA,. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest 2005; 127: 1205-1211.
128. Tattersfield AE, Harrison TW, Hubbard RB, Mortimer K,. Safety of inhaled corticosteroids. Proc Am Thorac Soc 2004; 1: 171-175.
129. Telenga ED, Kerstjens HA, Postma DS, Ten Hacken NH, van den Berge M,. Inhaled corticosteroids in chronic obstructive pulmonary disease: a review. Expert Opin Pharmacother 2010; 11: 405-421.
130. Singh S, Loke YK,. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2010; 5: 189-195.
131. Sin DD, Tashkin D, Zhang X, Radner F, Sjöbring U, Thorén A, Calverley PM, Rennard SI,. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374: 712-719.
132. Janson C, Larsson K, Lisspers KH, Ställberg B, Stratelis G, Goike H, Jörgensen L, Johansson G,. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS). BMJ 2013; 346: f3306.
133. Suissa S, Patenaude V, Lapi F, Ernst P,. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013; 68: 1029-1036.
134. Ernst P, Gonzalez AV, Brassard P, Suissa S,. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176: 162-166.
135. Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Willits LR, Yates JC, Vestbo J,. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009; 34: 641-647.
136. Suissa S, Kezouh A, Ernst P,. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010; 123: 1001-1006.
137. O'Byrne PM, Rennard S, Gerstein H, Radner F, Peterson S, Lindberg B, Carlsson LG, Sin DD,. Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. Respir Med 2012; 106: 1487-1493.
138. Jones A, Fay JK, Burr M, Stone M, Hood K, Roberts G,. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002; (1) CD003537.
139. Johnell O, Pauwels R, Löfdahl CG, Laitinen LA, Postma DS, Pride NB, Ohlsson SV,. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur Respir J 2002; 19: 1058-1063.
140. Brassard P, Suissa S, Kezouh A, Ernst P,. Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. Am J Respir Crit Care Med 2011; 183: 675-678.
141. Gartlehner G, Hansen RA, Carson SS, Lohr KN,. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med 2006; 4: 253-262.
142. Lipworth BJ,. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999; 159: 941-955.
143. Singanayagam A, Chalmers JD, Akram AR, Hill AT,. Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur Respir J 2011; 38: 36-41.
144. Singh S, Amin AV, Loke YK,. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009; 169: 219-229.
145. 2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; (9) CD006829.
146. Barnes PJ, Celli BR,. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165-1185.
147. Hubbard RB, Smith CJ, Smeeth L, Harrison TW, Tattersfield AE,. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med 2002; 166 (12 Pt 1): 1563-1566.
148. Lee TA, Weiss KB,. Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 855-859.
149. Loke YK, Cavallazzi R, Singh S,. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 2011; 66: 699-708.
150. Smeeth L, Boulis M, Hubbard R, Fletcher AE,. A population based case-control study of cataract and inhaled corticosteroids. Br J Ophthalmol 2003; 87: 1247-1251.
151. Cumming RG, Mitchell P, Leeder SR,. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337: 8-14.
152. Garbe E, Suissa S, LeLorier J,. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998; 280: 539-543.
153. Jick SS, Vasilakis-Scaramozza C, Maier WC,. The risk of cataract among users of inhaled steroids. Epidemiology 2001; 12: 229-234.
154. Weatherall M, Clay J, James K, Perrin K, Shirtcliffe P, Beasley R,. Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-analysis. Respirology 2009; 14: 983-990.
155. Garbe E, LeLorier J, Boivin JF, Suissa S,. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997; 277: 722-727.
156. Mitchell P, Cumming RG, Mackey DA,. Inhaled corticosteroids, family history, and risk of glaucoma. Ophthalmology 1999; 106: 2301-2306.
157. Slatore CG, Bryson CL, Au DH,. The association of inhaled corticosteroid use with serum glucose concentration in a large cohort. Am J Med 2009; 122: 472-478.
158. Lee CH, Kim K, Hyun MK, Jang EJ, Lee NR, Yim JJ,. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax 2013; 68: 1105-1113.
159. Andréjak C, Nielsen R, Thomsen VØ, Duhaut P, Sørensen HT, Thomsen RW,. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax 2013; 68: 256-262.
160. Sharafkhaneh A, Petersen NJ, Yu HJ, Dalal AA, Johnson ML, Hanania NA,. Burden of COPD in a government health care system: a retrospective observational study using data from the US Veterans Affairs population. Int J Chron Obstruct Pulmon Dis 2010; 5: 125-132.
161. Blanchette CM, Gutierrez B, Ory C, Chang E, Akazawa M,. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population. J Manag Care Pharm 2008; 14: 176-185.
162. Britton M,. The burden of COPD in the U.K.: results from the Confronting COPD survey. Respir Med 2003; 97 (Suppl C): S71-79.
163. Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S, Jameson K,. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Int J Chron Obstruct Pulmon Dis 2012; 7: 183-199.
164. Samyshkin Y, Schlunegger M, Haefliger S, Ledderhose S, Radford M,. Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland. Int J Chron Obstruct Pulmon Dis 2013; 8: 79-87.
165. Akazawa M, Stearns SC, Biddle AK,. Assessing treatment effects of inhaled corticosteroids on medical expenses and exacerbations among COPD patients: longitudinal analysis of managed care claims. Health Serv Res 2008; 43: 2164-2182.
166. Taneja A,. Bronchoscopic interventions in the management of chronic obstructive pulmonary disease. Curr Opin Pulm Med 2013; 19: 145-151.